Uncategorized
InSite quarterly revenue increases due to Nicox license agreement payment
InSite Vision reported $3.4 million in revenues in the first quarter 2015, an increase from $1.2 million in the first quarter of the previous year, according to a press release.The increase was attributed to a $3 million payment from a license agreement with Nicox to develop and commercialize AzaSite (1% azithromycin), AzaSite Xtra (2% azithromycin) and BromSite (0.075% bromfenac) in Europe, the Middle East and Africa, the release said.